About: Modulating cGMP to Treat Lung Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Modulating cGMP to Treat Lung Diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Modulating cGMP to Treat Lung Diseases
Creator	Grimminger, Friedrich Ghofrani, Hossein-Ardeschir
Source	PMC
abstract	Background: Nitric oxide (NO) is constitutively produced in the lung by NO-synthases. The main cellular sources of lung NO production are the vascular endothelium and the airway epithelia (Bohle et al. 2000; German et al. 2000; Ide et al. 1999). Local NO production contributes to regulation of pulmonary perfusion depending on alveolar ventilation to assure optimized ventilation/perfusion distribution (Grimminger et al. 1995). NO-synthase activity is regulated on transcriptional and post-translational redox-based modulation level. The common signaling pathway of endogenous vasodilators, such as nitric oxide, prostaglandins, and natriuretic peptides, engage cyclic nucleotides (cAMP and cGMP). These second messengers are mainly produced by activation of adenylate- and guanylate-cyclases, both membrane-bound and soluble (Beavo 1995). Phosphodiesterases (PDEs) represent a superfamily of enzymes, with PDE1 through PDE11 being currently known, that inactivate cyclic AMP and cyclic GMP, with different tissue distribution and substrate specificities (Ahn et al. 1991; Von Euler and Liljestrand. 1946). Because of stabilization of these second messengers, PDE inhibitors differentially regulate levels of cAMP and/or cGMP, depending on their selectivity profile. Recently, direct activators and stimulators of the sGC have been suggested as new therapeutic tools for the treatment of lung vascular disorders that might have even higher potency than PDE inhibitors or exogenously applied NO.
has issue date	2009-01-01(xsd:dateTime)
bibo:doi	10.1007/978-3-540-68964-5_20
bibo:pmid	19089341
has license	no-cc
sha1sum (hex)	2bf98d6bce57e6f71d07087fb9af3e345a42883b
schema:url	https://doi.org/10.1007/978-3-540-68964-5_20
resource representing a document's title	Modulating cGMP to Treat Lung Diseases
has PubMed Central identifier	PMC7121669
has PubMed identifier	19089341
schema:publication	cGMP: Generators, Effectors and Therapeutic Implications
resource representing a document's body	covid:2bf98d6bce57e6f71d07087fb9af3e345a42883b#body_text
is schema:about of	named entity 'pulmonary arterial hypertension' named entity 'medical community' named entity 'nitric oxide' named entity 'cyclic GMP' named entity 'vasodilation' named entity 'hemodynamics' named entity 'gas exchange' named entity 'pulmonary arterial hypertension' named entity 'HPV' named entity 'sildenafil' named entity 'nitric oxide' named entity 'intravenous' named entity 'pulmonary circulation' named entity 'short-term' named entity 'sildenafil' named entity 'molecule' named entity 'pathology' named entity 'long-term' named entity 'prostacyclin' named entity 'pulmonary arterial hypertension' named entity 'pulmonary pressure' named entity 'sildenafil' named entity 'distal' named entity 'pulmonary hypertension' named entity 'vasodilator' named entity 'blood flow' named entity 'primary end-point' named entity 'pulmonary hypertension' named entity 'prostacyclin synthase' named entity 'Bay 58-2667' named entity 'prostanoids' named entity 'lung transplantation' named entity 'oxidized' named entity 'gas exchange' named entity 'perfusion' named entity 'vasorelaxation' named entity 'cardiac output' named entity 'PGI' named entity 'cGMP' named entity 'vardenafil' named entity 'sildenafil' named entity 'Phosphodiesterases' named entity 'hemodynamics' named entity 'PDE' named entity 'pulmonary arterial hypertension' named entity 'controlled clinical trial' named entity 'vasoconstrictor' named entity 'iloprost' named entity 'pulmonary vascular' named entity 'lung fibrosis' named entity 'cGMP' named entity 'PDE5 inhibitor' named entity 'pulmonary hypertension' named entity 'Sildenafil' named entity 'protein expression' named entity 'enzyme' named entity 'safety profile' named entity 'adhesion' named entity 'resistance vessels' named entity 'nitric oxide' named entity 'prostacyclin' named entity 'pulmonary hypertension' named entity 'gas exchange' named entity 'desensitization' named entity 'soluble guanylate cyclase' named entity 'tadalafil' named entity 'perfusion' named entity 'Nitric oxide' named entity 'prostanoids' named entity 'dose-dependent manner' named entity 'lung' named entity 'vasodilators' named entity 'EMEA' named entity 'prostacyclin' named entity 'lung tissue' named entity 'hypoxic vasoconstriction' named entity 'sildenafil' named entity 'pulmonary hypertension' named entity 'lung fibrosis' named entity 'pulmonary vascular resistance'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software